Dengue Vaccine Enters Phase 3 Trial in Brazil
Investigational Vaccine to Prevent “Breakbone Fever” Developed at NIH
A large-scale clinical trial to evaluate whether a candidate vaccine can prevent the mosquito-borne illness dengue fever has been launched in Brazil. The vaccine, TV003, was developed by scientists in the laboratory of Stephen Whitehead, Ph.D., at NIH’s National Institute of Allergy and Infectious Diseases (NIAID). The Butantan Institute, a non-profit producer of immunobiologic products for Brazil, licensed the NIAID dengue vaccine technology and is sponsoring the placebo-controlled, multi-center Phase 3 trial using test vaccine produced in Sao Paulo.
A female Aedes aegypti mosquito ingesting a blood meal.
Credit: CDC
This page was last updated on Friday, January 21, 2022